Abstract:MK-801, an NMDA receptor antagonist, and scopolamine, a cholinergic receptor blocker, are widely used as tool compounds to induce learning and memory deficits in animal models to study schizophrenia or Alzheimer-type dementia (AD), respectively. Memory impairments are observed after either acute or chronic administration of either compound. The present experiments were performed to study the nitric oxide (NO)-related mechanisms underlying memory dysfunction induced by acute or chronic (14 days) administration of MK-801 (0.3 mg/kg, i.p.) or scopolamine (1 mg/kg, i.p.). The levels of L-arginine and its derivatives, L-citrulline, L-glutamate, L-glutamine and L-ornithine, were measured. The expression of constitutive nitric oxide synthases (cNOS), dimethylaminohydrolase (DDAH1) and protein arginine N-methyltransferases (PMRTs) 1 and 5 was evaluated, and the impact of the studied tool compounds on cGMP production and NMDA receptors was measured. The studies were performed in both the cortex and hippocampus of mice. S-nitrosylation of selected proteins, such as GLT-1, APP and tau, was also investigated. Our results indicate that the availability of L-arginine decreased after chronic administration of MK-801 or scopolamine, as both the amino acid itself as well as its level in proportion to its derivatives (SDMA and NMMA) were decreased. Additionally, among all three methylamines, SDMA was the most abundant in the brain (~70%). Administration of either compound impaired eNOS-derived NO production, increasing the monomer levels, and had no significant impact on nNOS. Both compounds elevated DDAH1 expression, and slight decreases in PMRT1 and PMRT5 in the cortex after scopolamine (acute) and MK-801 (chronic) administration were observed in the PFC, respectively. Administration of MK-801 induced a decrease in the cGMP level in the hippocampus, accompanied by decreased NMDA expression, while increased cGMP production and decreased NMDA receptor expression were observed after scopolamine administration. Chronic MK-801 and scopolamine administration affected S-nitrosylation of GLT-1 transport protein. Our results indicate that the analyzed tool compounds used in pharmacological models of schizophrenia or AD induce changes in NO-related pathways in the brain structures involved in cognition. To some extent, the changes resemble those observed in human samples.

Neuropeptide S Enhances Memory and Mitigates Memory Impairment Induced by MK801, Scopolamine or Aβ1–42 in Mice Novel Object and Object Location Recognition Tasks

Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice.

Neuropeptide S Ameliorates Olfactory Spatial Memory Impairment Induced by Scopolamine and MK801 Through Activation of Cognate Receptor-Expressing Neurons in the Subiculum Complex

Neuropeptide S Displays As a Key Neuromodulator in Olfactory Spatial Memory.

Neuropeptide S Interacts with the Basolateral Amygdala Noradrenergic System in Facilitating Object Recognition Memory Consolidation

Neuropeptide S overcomes short term memory deficit induced by sleep restriction by increasing prefrontal cortex activity

Neuropeptide S promotes maintenance of newly formed dendritic spines and performance improvement after motor learning in mice

Central treatment of neuropeptide-S attenuates cognitive dysfunction and hippocampal synaptic plasticity impairment by increasing CaMKII/GluR1 in hemiparkinsonian rats

Neuropeptide S Facilitates Mice Olfactory Function Through Activation Of Cognate Receptor-Expressing Neurons In The Olfactory Cortex

Neuropeptide S Attenuates the Alarm Pheromone-Evoked Defensive and Risk Assessment Behaviors Through Activation of Cognate Receptor-Expressing Neurons in the Posterior Medial Amygdala

Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior]

Improvement of cationic albumin conjugated pegylated nanoparticles holding NC-1900, a vasopressin fragment analog, in memory deficits induced by scopolamine in mice

Peripheral Administration of a Cell-Penetrating MOTS-c Analogue Enhances Memory and Attenuates Aβ1-42- or LPS-Induced Memory Impairment Through Inhibiting Neuroinflammation.

Phoenixin-14 enhances memory and mitigates memory impairment induced by Aβ1-42 and scopolamine in mice.

Neuropeptide S inhibits the acquisition and the expression of conditioned place preference to morphine in mice.

Neurochemical Mechanisms of a Novel Alzheimer′s Disease Therapeutics on Improvement of Cognition and Depressive Behavior

Spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one (ZSET1446/ST101) Treatment Rescues Olfactory Bulbectomy-Induced Memory Impairment by Activating Ca2+/Calmodulin Kinase II and Protein Kinase C in Mouse Hippocampus

Nitric Oxide-Dependent Mechanisms Underlying MK-801- or Scopolamine-Induced Memory Dysfunction in Animals: Mechanistic Studies

Self-Assembling Modified Neuropeptide S Enhances Nose-To-Brain Penetration And Exerts A Prolonged Anxiolytic-Like Effect

Neuropeptide S Attenuates Methamphetamine-Induced Stereotyped Behavior in Rats.

Propane-2-sulfonic acid octadec-9-enyl-amide alleviates scopolamine-induced spatial learning and memory deficits in mice